Profound Medical (PROF) launches global ‘Let’s Huddle’ prostate patient community

Rhea-AI Filing Summary

Profound Medical Corp., a commercial-stage medical device company focused on interventional MRI (iMRI) procedures, reported the launch of Let’s Huddle, a global patient advocacy and community initiative supporting men and their families through the prostate care journey. Announced on August 13, 2026, the program is led by Global Patient Ambassador Leonard Wheeler, a former NFL player and prostate cancer survivor, and is designed to provide education, peer connection, survivor stories, and resources for patients and care partners.

The initiative aligns with Profound’s MRI-guided therapy platforms TULSA-PRO and Sonalleve by extending support beyond treatment delivery to include pre-diagnosis education, treatment decision support, and survivorship. Profound states that Let’s Huddle will grow through expanded educational programming, storytelling, awareness campaigns, and collaborations with healthcare providers and advocacy organizations worldwide.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Launch date of Let’s Huddle: August 13, 2026 TULSA-PRO status in U.S.: FDA-cleared Sonalleve status in U.S.: FDA HDE

3 metrics

Launch date of Let’s Huddle August 13, 2026 Date of press release announcing the Let’s Huddle initiative

TULSA-PRO status in U.S. FDA-cleared Cleared for transurethral ultrasound ablation (TULSA) of prostate tissue

Sonalleve status in U.S. FDA HDE Approved as Humanitarian Device Exemption for osteoid osteomas in extremities

Key Terms

interventional MRI, TULSA-PRO, TULSA Procedure, HDE, +1 more

5 terms

interventional MRI medical

"an innovator in interventional MRI (iMRI) procedures"

Interventional MRI is the use of magnetic resonance imaging machines during medical procedures to guide needles, catheters or surgical tools in real time, like using a live GPS map inside the body instead of relying on static pictures. For investors, it matters because hospitals and device makers adopting this technology can change procedure costs, reduce complications and open new markets for specialized scanners, instruments and software, affecting revenue, reimbursement and competitive positioning.

TULSA-PRO medical

"The company’s flagship platform, TULSA-PRO®, enables MRI-guided"

TULSA Procedure medical

"Physicians use the TULSA Procedure to see, ablate, and confirm therapy in real time"

The Tulsa procedure is a minimally invasive medical treatment for an enlarged prostate that uses targeted pulses of sterile water vapor to destroy excess tissue and relieve urinary blockage. For investors, its clinical adoption, reimbursement status, and ease of use influence demand for the devices, shift patient flow away from long‑term drugs or major surgery, and can materially affect revenue and growth for device manufacturers, hospitals and urology clinics — like a new tool that changes how often and where a condition gets treated.

HDE medical

"Sonalleve is approved by the FDA as HDE in the United States"

HDE stands for Humanitarian Device Exemption, an FDA pathway that allows medical devices intended to diagnose or treat rare conditions to reach the market with a lower burden of clinical evidence than usual. Think of it like a special permit for products aimed at very small patient groups; it gives regulatory access more quickly but still limits how the device can be promoted and reimbursed. For investors, an HDE can shorten time to sales and shape the size and predictability of future revenue while carrying specific regulatory and market constraints.

palliative pain medical

"provides a non-surgical treatment option for pain palliation of bone metastases"

FAQ

What did Profound Medical (PROF) announce regarding patient support?

Profound Medical announced Let’s Huddle, a global patient advocacy community for men with prostate disease. It focuses on education, peer support, survivor stories, and resources for patients, families, and care partners across the entire prostate care journey.

What is the purpose of Profound Medical’s Let’s Huddle initiative for PROF investors to know?

Let’s Huddle aims to educate and connect prostate patients, survivors, and families, helping them navigate diagnosis, treatment decisions, and survivorship. The initiative supports more informed patient engagement and complements Profound’s MRI-guided treatment technologies.

Who is leading the Let’s Huddle community for Profound Medical (PROF)?

The Let’s Huddle community is led by Leonard Wheeler, Profound’s Global Patient Ambassador, a former NFL player, prostate cancer survivor, and men’s health advocate. He shares his journey, elevates survivor voices, and promotes education and engagement in prostate health.

How does Let’s Huddle relate to Profound Medical’s TULSA-PRO platform (PROF)?

Profound links Let’s Huddle to its TULSA-PRO MRI-guided prostate ablation platform by extending support beyond the procedure. The community focuses on education, advocacy, and survivorship for men considering or undergoing prostate treatments, including the TULSA Procedure.

What types of resources will Profound Medical’s Let’s Huddle provide?

Let’s Huddle will provide educational materials on prostate disease and treatments, real patient stories, peer-to-peer engagement, survivorship support, resources for family members and care partners, and awareness and advocacy initiatives focused on prostate health.

When did Profound Medical (PROF) launch the Let’s Huddle initiative?

Profound Medical launched the Let’s Huddle initiative on August 13, 2026. The company described it as a global patient community intended to support men with prostate disease and their families throughout diagnosis, treatment decisions, and long-term survivorship.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Available on EDGAR 08/13/2026 - 04:31 PM Accepted by SEC EDGAR 08/13/2026 - 04:30 PM Learn about SEC filing dates

False000162880800016288082026-08-132026-08-13iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  August 13, 2026

_______________________________

PROFOUND MEDICAL CORP.

(Exact name of registrant as specified in its charter)

_______________________________

Ontario, Canada	001-39032	Not Applicable
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

2400 Skymark Avenue, Unit 6

Mississauga, Ontario, Canada L4W 5K5

(Address of Principal Executive Offices) (Zip Code)

Registrant's Telephone Number, Including Area Code: 647-476-1350

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Shares	PROF	The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On August 13, 2026, Profound Medical Corp. (the “Company” or “Profound”) issued a press release announcing the launch of Let’s Huddle, a patient advocacy initiative. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or the Exchange Act, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, or the Securities Act. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the U.S. Securities Exchange Commission, or the SEC, made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release, dated August 13, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PROFOUND MEDICAL CORP.
Date: August 13, 2026	By:	/s/ Rashed Dewan
		Rashed Dewan
		Chief Financial Officer

EXHIBIT 99.1

Profound Medical Launches ‘Let's Huddle’, a Global Community Supporting Men Throughout Their Prostate Care Journey

A patient-centered initiative focused on education, connection, and support

TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (“iMRI”) procedures, today announced the launch of Let's Huddle, a global patient community designed to empower men and their families with education, connection, and support throughout every stage of the prostate care journey.

The new patient advocacy initiative, led by Leonard Wheeler, Profound’s Global Patient Ambassador, former NFL player, prostate cancer survivor, and men's health advocate, brings together patients, survivors, care partners, healthcare professionals, and advocates with a shared mission: to change the conversation around prostate disease through education, awareness, and authentic patient experiences.

Let’s Huddle reflects Profound’s belief that innovation extends beyond technology—it includes helping patients feel informed, supported, and confident as they navigate complex treatment decisions. Through education, peer connection, and advocacy, the Let's Huddle community helps empower patients to take an active role in their care while advancing better outcomes for the broader patient community.

"Receiving a prostate disease diagnosis can be overwhelming, and many men struggle to find trusted information and connect with others who truly understand what they're experiencing," said Tom Tamberrino, Profound’s Chief Commercial Officer. "Let's Huddle was created to ensure that no one has to navigate that journey alone. By fostering education, peer support, and meaningful conversations, we're helping patients become more informed participants in their care while building a stronger community around prostate health. This initiative reflects our commitment to improving the patient experience before diagnosis, during treatment, and long into survivorship."

Mr. Wheeler will help lead the Let's Huddle community by sharing his personal journey, elevating survivor voices, participating in educational initiatives, and encouraging men to become more informed and engaged in their prostate health.

"As someone who has lived through a prostate cancer diagnosis, I know firsthand how isolating the journey can feel," said Mr. Wheeler. "The information your physician provides is critical, but there's something uniquely powerful about connecting with someone who's already walked the path. Let's Huddle creates a place where men and their families can learn, ask questions, share their stories, and realize they're not facing prostate disease alone. I'm honored to help lead this initiative with Profound because together we can change how prostate disease is talked about and empower more men to take charge of their health."

Terrell Freeman, a U.S. military veteran, TULSA Procedure™ patient, and active member of the Let's Huddle community, knows firsthand the impact that patient-to-patient support can have during the treatment journey.

"Hearing from someone who had already walked this path gave me the confidence I needed during one of the most challenging decisions of my life,” Mr. Freeman commented. “Knowing there was someone I could relate to made all the difference. That's why I'm proud to be part of Let's Huddle. Every man deserves access to real experiences, honest conversations, and a community of men and women that reminds him he doesn't have to face prostate disease alone."

Research consistently shows that hearing directly from patients who have experienced similar diagnoses and treatments is one of the most valuable resources for individuals making treatment decisions. Let's Huddle provides a trusted platform where survivors can share their experiences, patients can access educational resources, and care partners can find support—helping men engage in more informed conversations with their physicians and feel more confident throughout their care journey.

Supporting the Entire Patient Journey

As healthcare increasingly embraces patient-centered care, Let's Huddle expands Profound’s commitment beyond treatment delivery by supporting individuals before diagnosis, during treatment selection, and throughout survivorship.

The Let’s Huddle community will provide:

• Educational resources to help patients better understand prostate disease and available treatment options.
• Real patient stories and experiences that provide perspective and encouragement.
• Opportunities for peer-to-peer engagement and survivorship support.
• Resources for family members and care partners navigating the journey alongside loved ones.
• Awareness initiatives that encourage earlier conversations about prostate health.
• Opportunities to advocate for better care pathways for prostate disease.

Creating Value Beyond Technology

While Profound continues to advance MRI-guided therapies through TULSA-PRO^®, the Company recognizes that technology alone does not define the patient experience.

Let's Huddle demonstrates Profound's commitment to the entire continuum of care—from diagnosis through survivorship. By investing in education, advocacy, and community engagement, the company is helping healthcare organizations strengthen patient education, build trust within their communities, and reinforce their commitment to comprehensive, patient-centered care.

"When healthcare organizations invest in TULSA-PRO, they're not simply adopting an innovative treatment platform," added Mr. Tamberrino. "They're joining a growing ecosystem dedicated to patient education, engagement, advocacy, and survivorship—helping providers deliver meaningful value before, during, and long after treatment."

As the Let's Huddle community grows, Profound will expand educational programming, patient storytelling initiatives, awareness campaigns, and collaborations with healthcare providers and advocacy organizations worldwide—all with the goal of improving how prostate disease is discussed, understood, and treated.

About Profound Medical Corp.

Profound is a commercial-stage medical device company and an innovator in interventional MRI (iMRI) procedures. The company’s flagship platform, TULSA-PRO^®, enables MRI-guided, incision-free prostate ablation. Physicians use the TULSA Procedure to see, ablate, and confirm therapy in real time, supporting personalized treatment strategies across the continuum of prostate care—from whole-gland to subtotal, hemi, multifocal, and focal treatment. This approach enables individualized care using prostate tissue ablation, while minimizing the potential of the side effects that are typically associated with surgery or radiation, such as urinary incontinence and/or erectile dysfunction.

Profound also commercializes Sonalleve^®, an MRI-guided therapy that provides a non-surgical treatment option for pain palliation of bone metastases, desmoid tumors, and osteoid osteoma, as well as for common gynecologic conditions including uterine fibroids and adenomyosis. Sonalleve delivers targeted therapy with no incisions, no blood loss during the procedure, no overnight hospital stay, and faster recovery — and, in gynecologic applications, enables uterine-sparing treatment that may help preserve fertility. Profound is also exploring additional clinical applications for Sonalleve, including non-invasive ablation of abdominal cancers and hyperthermia-based cancer therapies.

Profound Medical’s technologies are approved across major global markets. TULSA-PRO is cleared by the FDA in the United States for transurethral ultrasound ablation (TULSA) of prostate tissue. In addition, TULSA-PRO is cleared for use in various jurisdictions including Europe, Canada, Saudi Arabia, India, Australia/New Zealand, and the UAE. Sonalleve is approved by the FDA as HDE in the United States for the treatment of osteoid osteomas in the extremities. Sonalleve is also cleared or approved in the Europe, Canada, China, and Saudi Arabia.

Through real-time MRI guidance and data-driven innovation, Profound is advancing the future of MRI-guided therapy — expanding access to precise, personalized, and incision-free treatment options worldwide.

Forward-Looking Statements

This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, the expectations regarding the efficacy of Profound’s technologies for disease conditions requiring MR-Guided ablation procedures for prostate, uterine fibroids, adenomyosis, palliative pain treatment, desmoid tumors, and osteoid osteoma; Profound’s expectations for future revenues/financial results; and the success of Profound’s commercialization strategy and activities for TULSA-PRO^® and Sonalleve^®. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, regulatory approvals, reimbursement, economic factors, the equity markets generally and risks associated with growth and competition. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Other factors and risks that may cause actual results to differ materially from those set out in the forward-looking statements are described in Profound's Annual Report on Form 10-K and other filings made with U.S. and Canadian securities regulators, available at www.sedarplus.com and www.sec.gov. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.

For further information, please contact:

Susan Thomas
Public Relations
sthomas@profoundmedical.com
T: 619.540.9195

Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com   
T: 647.872.4849

A video accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8fa2ec84-cdd0-4060-aca1-fd4433457efc

Filing Exhibits & Attachments

5 documents

Press Releases

• EX-99.1 PRESS RELEASE 13.1 KB

Other Documents

• EX-101 XBRL SCHEMA FILE 3.3 KB
• EX-101 XBRL DEFINITION FILE 25.5 KB
• EX-101 XBRL LABEL FILE 35.1 KB
• EX-101 XBRL PRESENTATION FILE 24.1 KB